Thursday, June 25, 2026
🇺🇸 FDA

Regulatory Tools — Submission Operations

Regulatory Submission Timeline Builder

Build indicative IND, NDA, BLA, and EMA MAA milestone calendars from a planning start date. Built for regulatory affairs, submission managers, and small biotech teams — export CSV for ops handoff.

Quick Answer

This free regulatory submission timeline builder generates indicative IND, NDA, BLA, and EMA MAA milestone calendars from a planning start date — including pre-IND and pre-NDA/pre-BLA meetings, eCTD submission targets, FDA 30-day safety review, PDUFA action windows, and EMA clock-stop phases. Export milestones to CSV for RA ops handoff. Planning support only; confirm all dates against FDA CDER correspondence, EMA procedure rules, and product-specific strategy.

Timeline Sequences Included

IND

Pre-IND engagement, IND submission, 30-day FDA review, study activation

NDA / BLA

Pre-submission meeting, application submission, filing, review, PDUFA target

EMA MAA

Validation, assessment days, clock stop, CHMP opinion, EC decision

Timeline Builder

Select a pathway and start date, then generate a milestone plan.

Submission sequence
Review assumptions

Generated sequence

-

-

Milestone Target date Offset Operations note

-

How to Use the Submission Timeline Builder

  1. Select IND, NDA, BLA, or EMA MAA depending on whether you are planning first-in-human enablement or marketing authorization.
  2. Enter a planning start date — typically a pre-IND or pre-NDA/pre-BLA meeting request date, or MAA kickoff.
  3. For NDA/BLA, choose standard (10-month) or priority (6-month) review from filing; for MAA, enter expected clock-stop days for applicant responses.
  4. Review milestones, operations notes, and caveats; download CSV and import into your RA project tracker with owners and eCTD module dependencies.

Worked Example

Scenario: Small-molecule NDA with standard review; pre-NDA meeting request anchored January 2, 2026.

Pre-NDA meeting target: ~March 3, 2026 (+60 days).

NDA submission target: ~July 1, 2026 (+180 days) — back-plan eCTD module publishing from this date.

Filing decision target: ~August 30, 2026 (+60 days from submission).

Estimated PDUFA action: ~June 30, 2027 (+10 months from filing). Confirm with our PDUFA Date Calculator once FDA accepts the filing.

Milestone Reference by Pathway

Pathway Key milestones Typical review clock Critical ops dependency
IND Pre-IND, IND file, 30-day review, site activation 30-day FDA safety review CMC, tox, protocol, IB readiness; IRB and site contracts
NDA Pre-NDA, submission, filing, mid/late cycle, PDUFA 10 mo standard / 6 mo priority from filing eCTD publishing, integrated summaries, labeling, inspection readiness
BLA Pre-BLA, submission, filing, mid/late cycle, PDUFA 10 mo standard / 6 mo priority from filing Manufacturing, comparability, lot release, facility inspections
EMA MAA Validation, Day 120 LoQ, clock stop, CHMP, EC decision Procedure-specific; user-entered clock stop Module readiness, rapporteur Q&A, oral explanation risk

Regulatory Operations Caveats

Document readiness CMC, nonclinical, clinical, labeling, regional forms, publishing, and quality control can drive the real critical path.
Agency correspondence Meeting minutes, filing letters, validation notices, list of questions, and review communications should control official plans.
Inspections and responses Facility inspections, data-integrity issues, REMS, labeling, and question-response cycles can change target dates materially.

Pharma & regulatory affairs context

Submission planning for small biotech and emerging pharma teams typically begins 12–18 months before the target filing date — covering document-specific trackers, by-discipline risk assessments, and cross-functional alignment on labeling and CMC readiness. A Gantt chart alone is insufficient; RA ops need milestone tables tied to eCTD module handoffs, agency meetings, and review clocks.

Pair this builder with our FDA Submission Types Guide to confirm pathway (IND, NDA, BLA, 505(b)(2)), the eCTD Structure Guide for module publishing sequences, and PDUFA tools — PDUFA Date Calculator and PDUFA Calendar 2026 — for post-filing review clocks. For first-in-human programs, see the IND Guide.

The CSV export is intentionally simple: milestone, target date, offset, and operations note. Import it into a project tracker, add owners, dependencies, document modules, publishing tasks, QC checkpoints, and agency correspondence links. For cross-regional programs, keep US and EU timelines separate until document strategy, data cut, labeling, manufacturing package, and inspection readiness assumptions are aligned.

Evidence & sources

Competitive landscape: Synerg BioPharma's RA consulting blog (Planning Your NDA or BLA Submission) recommends 12–18 month submission planning with trackers and key-messages documents — editorial guidance, not an interactive builder. Meegle (Regulatory Submission Timeline Tracker) offers a gated PM template signup, not a free instant drug NDA/BLA/MAA planner. NextGen MedTech (Simple Regulatory Submission Tracker) provides an Excel download focused on FDA 510(k)/PMA medtech pathways. NovaPharmaNews combines a free browser milestone builder with CSV export and PDUFA/eCTD cluster links for drug RA teams.

Frequently Asked Questions

A regulatory submission timeline is an operational planning calendar that maps key preparation, submission, validation, review, response, and decision milestones for a development or marketing application. It connects document readiness, agency meetings, publishing, and cross-functional review cycles to target dates.
No. This builder provides indicative milestone dates only. Official plans should be built from agency correspondence, product strategy, regional procedure rules, document readiness, inspection readiness, and regulatory operations constraints. Treat output as a starting scaffold, not a filing commitment.
An IND timeline focuses on enabling first human studies: pre-IND engagement, IND submission, the 30-day FDA safety review window, and study activation. NDA and BLA timelines focus on marketing application filing, FDA filing acceptance, review cycles, labeling, inspections, and PDUFA action dates. IND milestones are shorter and study-centric; NDA/BLA milestones span months of review.
NDA and BLA user-fee goal structures are similar under PDUFA, but BLAs often require heavier biologics manufacturing, comparability, facility, and lot-release planning. Product center assignment (CDER vs CBER), inspection readiness, and module content can materially affect operations even when review clocks look identical.
An EMA MAA timeline is procedure-specific and includes validation, assessment phases, clock stops, CHMP opinion, and European Commission decision. Actual timing depends on questions, responses, oral explanations, rapporteur workload, and committee calendar. The user-entered clock-stop duration models applicant response time between Day 120 and restart.
IND milestones center on study enablement (pre-IND, 30-day review, site activation). NDA/BLA milestones center on marketing authorization (pre-submission meeting, complete application filing, filing decision, mid-cycle, PDUFA target). MAA milestones follow EU centralized/decentralized procedure phases (validation, Day 120 LoQ, clock stop, CHMP, EC decision). Each pathway uses different agency clocks and document packages.
eCTD module handoff dates should appear weeks before the submission target — typically Module 2 summaries after Module 5 clinical lock, Module 3 CMC after batch records and stability, and Module 1 regional forms after labeling alignment. Our NDA/BLA sequence anchors a submission target at +180 days from planning start; back-plan module publishing, validation, and QC from that date using our eCTD Structure Guide.
A complete application is submitted in one filing when all required modules are ready. Rolling submission (where FDA agrees) allows discrete eCTD modules or sections to be submitted as they become available, potentially starting review before the full dossier is filed. Rolling plans require prior FDA agreement and change milestone sequencing — this builder models complete-application timing by default.
FDA Type B pre-NDA and pre-BLA meetings are typically requested roughly two to three months before the planned submission to align on format, content, labeling, inspection risk, and review issues. Our builder anchors a pre-submission meeting request at Day 0 and a meeting target at +60 days, with submission at +180 days — adjust to your product-specific FDA correspondence.
CSV export lets regulatory operations teams import indicative milestones into project-management tools (Smartsheet, MS Project, Asana), working calendars, or cross-functional review trackers. Columns include milestone name, target date, ISO date, offset, and operations note — add owners, dependencies, and eCTD module links in your tracker.
This builder estimates PDUFA action targets from a planning start date and review assumption (standard 10 months or priority 6 months from filing). For filing-date-driven PDUFA math, use our PDUFA Date Calculator and map catalysts on the PDUFA Calendar 2026. Submission timelines cover the full RA ops path; PDUFA tools focus on the review clock after FDA accepts the filing.
Yes. Small biotech and emerging pharma RA teams often lack enterprise submission software. This free browser builder provides an instant IND/NDA/BLA/MAA milestone scaffold with CSV export — complementing FDA CDER desk references and consulting playbooks without gated SaaS signup or Excel-only device trackers.

Related Regulatory Tools

PDUFA Date Calculator PDUFA Calendar 2026 eCTD Structure Guide FDA Submission Types Guide IND Guide

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.